TABLE 11.2 (Continued)

Clinical trials involving adenovirus vector^a

Vector

Target

Disease

Number of

trials in phase

1/2 and 2, 3,

& 4

NCT number

1 (phase 3)

NCT03964415

Malaria

3 (phase 1/2)

NCT01397227;

NCT00392015;

NCT03203421

1 (phase 2)

NCT01366534;

Hepatits C virus

1 (phase 1/2)

NCT02309086

Ebola virus

1 (phase 1/2)

NCT02661464;

9 (phase 2)

NCT04028349;

NCT04186000;

NCT02598388;

NCT02564523;

NCT04711356;

NCT03929757;

NCT02416453;

NCT02876328;

NCT02575456

6 (phase 3)

NCT02661464;

NCT04152486;

NCT02509494;

NCT04228783;

NCT04556526;

NCT02543567

Tuberculosis

1 (phase 1/2)

NCT01017536

1 (phase 2)

NCT01198366

Rotavirus

1 (phase 3)

NCT01305109

Therapeutic

cancer

vaccines

Colon/breast/

head/neck/

renal

7 (phase 1/2)

NCT01147965;

NCT03127098;

NCT02423902;

NCT01042535;

NCT03754933;

NCT02842125;

NCT02879760

8 (phase 2)

NCT04111172;

NCT03050814;

NCT01703754;

NCT00044993;

NCT00017173;

NCT00617409;

NCT00776295;

NCT00704938

(Continued)

Vectored vaccines

273